Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 24, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification of share transactions and does not contain financial performance data.
Material Changes
The filing details a specific transaction on September 6, 2005, where Abacus (GSK) Trustees Limited, acting as trustee for the GlaxoSmithKline Employee Trust ("the GSK Trust"), transferred 50,880 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The Company was advised of these transactions on September 7, 2005.
Management Commentary and Risks
The GSK Trust is identified as a discretionary trust where all current and former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. The filing notes that three directors—Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop—hold an interest in the shares held within the GSK Trust in the same capacity as other employees. No other risks, contingencies, or unusual items are disclosed in this text.
Investor Verification Points
- Verify the total number of shares transferred (50,880) and the specific plan involved (SmithKline Beecham Employee Share Option Plan 1991).
- Confirm the date of the transaction (September 6, 2005) versus the date the Company was advised (September 7, 2005).
- Review the status of the GSK Trust as a discretionary trust for employee beneficiaries.
- Note that this filing does not contain financial results; investors should refer to Form 20-F for financial data.